Point-of-Care Molecular Diagnostics Market
Report ID: SQMIG35J2327
Report ID: SQMIG35J2327
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2327 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
120
|Figures:
77
Global Point-Of-Care Molecular Diagnostics Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.5 Billion in 2025 to USD 22.85 Billion by 2033, growing at a CAGR of 11.52% during the forecast period (2026-2033).
Molecular diagnostics at point-of-care include the use of portable and quick devices providing DNA and RNA testing right at the patient site, rather than using conventional laboratory methods, and the key reason behind the increased demand for such technologies has been the pressing necessity of obtaining timely results to make the next steps. From an evolutionary perspective, point-of-care diagnostics was initially represented by bulky PCR devices located in central labs and turned into portable devices as a result of progress made in such fields as microfluidics, reagent stabilization and sample preparation. Such events like the coronavirus pandemic pushed the development further.
There are many factors that play their role, but regulatory alignment and reimbursement of the testing process can be considered as one of the major factors, since once there is clarity in terms of approval processes from the regulatory authority and also the test becomes economically feasible for reimbursement by payers, then there is a significant investment put by the manufacturing companies in developing the product and health care facilities adopting the technology into their process. This leads to the expansion of multiplex platforms and reduction in the cost of individual test, thus resulting in increased adoption of tests in emergency settings and other settings like clinics.
How is AI Enhancing Accuracy and Speed in the Point-of-care Molecular Diagnostics Market?
AI increases the accuracy and speed of point of care molecular diagnostics through an integration of cutting-edge signal processing technology, automated quality control and clinical decision support system. Machine learning models that improve raw signal analysis, imaging-based analysis that standardizes readouts and embedded algorithms that assist in sample processing and detection of errors are some of the important features of AI in molecular diagnostics. Currently, there is a growing trend in moving the molecular diagnostics industry towards decentralized point of care testing with microfluidic systems, CRISPR sensors and smarter lateral flow assays where AI will play an important role in reducing user dependency and time to results. This makes such testing methods more accurate and easy to implement in clinics and near-patient settings. Athelas February 2026, received FDA clearance for a CLIA waived device incorporating AI-based interpretation at point of care testing sites.
Market snapshot - (2026-2033)
Global Market Size
USD 8.52 Billion
Largest Segment
PCR-Based
Fastest Growth
CRISPR-Based
Growth Rate
11.52% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global point-of-care molecular diagnostics market is segmented by technology, disease, end-user and region. Based on technology, the market is segmented into PCR-Based, Isothermal Amplification (LAMP), CRISPR-Based and Microarray. Based on disease, the market is segmented into Respiratory Infections, STIs, Sepsis and Antibiotic Resistance. Based on end-user, the market is segmented into Hospitals, Primary Care Clinics, Pharmacies and Home Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
PCR-Based Segment holds the largest portion in the market share because the reliability and validity of its processes establish what is considered to be the highest quality benchmarking standard when diagnosing via molecular diagnosis. Valid chemistry reagents in conjunction with small size devices and well-established logistical considerations create a consistent and predictable process. Regulatory acceptability and physician confidence also reduce hurdles and make it easier to buy a valid near-patient device.
On the other side, the Isothermal Amplification (LAMP) segment will be the most dynamic growth market segment because of simpler thermal cycling needs making it possible to develop portable and low-power devices for decentralized testing. The combination of quick reaction time, simplistic instrumentation, and advancements in reagents makes this possible.
Hospitals category is leading since the acute care setting has higher acuity diagnostics requirements, and can leverage near-patient molecular diagnostic tools. The centralized approach to laboratory management and information technology systems enable use of sophisticated instruments that are integrated into electronic health record and help in timely decisions about infections and antibiotic resistance. Consequently, this helps in sustaining the demand for POCT molecular solutions.
In contrast, the Pharmacies category is the fastest growing due to the emergence of retail healthcare facilities and their adoption of molecular diagnostics in their services. The convenience and long opening hours of these facilities make it easy to deploy portable molecular diagnostic systems.
To get detailed segments analysis, Request a Free Sample Report
North America leads in the global point-of-care molecular diagnostics market because of the alignment of an advanced health system, strong industry presence, and favorable regulatory and reimbursement landscapes. The presence of an extensive ecosystem involving diagnostic companies, emerging technology firms, and research institutions fosters technology development and commercialization. The availability of a highly integrated healthcare landscape facilitates the rapid adoption of products and technologies. Favorable investment landscape and collaboration among various industry and clinical partners encourage the validation of tests and strengthen the supply chain capabilities. Moreover, the focus on personalized medicine and managing infections encourages decentralized point-of-care testing solutions. Collectively, all these factors contribute to establishing North America as an advanced marketplace where technology, access, and adoption synergize to maintain leadership at the global level.
US Point-of-Care Molecular Diagnostics Market is known for its high levels of commercialization capabilities, robust private investments, and well-developed clinical infrastructure. In fact, the market leaders and innovative players in the field team up with research centers and hospital organizations for validation and rapid implementation purposes. Reimbursement models along with well-equipped laboratories make sure that the technology can be adopted within hospitals, urgent care centers, and clinics, cementing the country’s place as the leader in innovation and adoption.
The Point-of-Care Molecular Diagnostics Market in Canada is characterized by the emphasis placed on equal access and integration within public healthcare systems. This is made possible through provincial procurement plans and partnerships that facilitate the use of the technology in urban and rural settings, especially in clinics and mobile testing sites. Research institutes and local manufacturing companies work together in developing these technologies, which are then adopted using health technology assessments.
Rapid growth in the molecular diagnostics market at the point of care in Europe is being propelled by policies favoring decentralization, sound public healthcare systems, and investments made towards advancing diagnostics. There is an increasing awareness among healthcare authorities and payers regarding the importance of rapid molecular testing for infectious diseases and antibiotic stewardship, which results in the implementation of trials for clinical application of such tests in hospitals and primary care practices. The medtech industry has a solid foundation in Europe along with partnerships between manufacturers, research institutes, and healthcare practitioners, which contributes to rapid product introduction to the market. Increasing standardization, emphasis on digital health, and initiatives aimed at procuring new technology will further enable expansion of the European market.
POC Molecular Diagnostic Market - Germany enjoys an established diagnostics landscape, an industrial base, and an advanced infrastructure of hospitals and laboratories that can enable quick deployment into clinical practice. A strong relationship between vendors, centers of clinical research, and buyers facilitates assessment and deployment of devices. Reimbursement policies and institutional purchasing ensure deployment in acute care environments like EDs and OPDs, cementing Germany’s position as a prominent market in Europe for POC molecular diagnostics.
Point of Care Molecular Diagnostics UK Market displays fast uptake facilitated by health system strategies, innovation clusters, and a strong focus on incorporating diagnostic solutions in primary care workflow. Industry collaborations and support from diagnostic hubs aid in faster clinical deployment and scale-up of solutions in community and acute settings. The policy orientation towards improved accessibility of molecular tests and faster validation & procurement procedures drives market growth and provides the necessary landscape for business expansion.
Point-of-Care Molecular Diagnostics Market France currently finds itself evolving towards the concept of decentralization of molecular testing and improved diagnosis in outpatients' care through investments in pilot projects. The joint efforts of national health institutions, research organizations, and local companies ensure clinical verification and manufacturing of products locally. Attention is paid to integration of point-of-care diagnostics in antibiotic stewardship, emergency medicine, and community health. Strategic changes in procurement policies and regional pilot schemes help make the country one of the new entrants in the European market.
Asia Pacific's influence in the Point-of-Care Molecular Diagnostics space is rising on the basis of manufacturing capabilities, effective public policies, and thriving innovation. Medtech organizations based in Asia Pacific are working towards creating affordable and scalable platforms capable of meeting varied requirements, whereas there is a focus on facilitating decentralization of testing within government agencies and healthcare organizations. Regulatory reforms alongside increased cooperation among manufacturers, local research institutions, and global players aid in the commercialization and cross-border trade of products. Efforts made towards building capacity in terms of digital technologies, supply chains, and manufacturing ensure that point-of-care platforms are accessible within hospitals, clinics, and community sites. All of this means that Asia Pacific's influence in the field will only grow from here onwards.
Japan exhibits advanced technology capability, well-developed networks for clinical research, and a stringent approach towards regulation, which ensures an assessment and deployment process of advanced diagnostics is carried out effectively. Existing medical device and diagnostics companies work together with hospitals and research centers in order to incorporate point-of-care molecular diagnostics in hospitals, homes, and the community at large. Quality, integration with IT systems, and innovative practices play an important role in successful commercialization in the country.
South Korea PoC Molecular Diagnostics Market The South Korean PoC Molecular Diagnostics Market is supported by a flexible biotech environment, robust production capabilities, and favorable public-private partnerships that speed up the innovation process. The quick adoption of digital health, effective partnership between the industry and medical communities, and the emphasis on export-oriented commercialization allow for scaling the solution within and outside of the country. Adaptive regulation and fast validation/deployment processes ensure quick integration of molecular tests in healthcare facilities and specialized clinics.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Need for Rapid Diagnosis
Fast and precise diagnosis either on or around the patient reduces the time spent making decisions for treatment and leads to efficient workflows. This motivates healthcare facilities to invest in point-of-care molecular diagnostics because they are interested in technologies that provide fast and effective diagnosis, which will help them to implement treatment programs. Clinical value motivates organizations to make such investments, and companies to increase product portfolios, thus facilitating market development and providing fast and effective solutions.
Expansion of Test Menu Offerings
Expanding the number of pathogens and conditions that can be identified using POC molecular testing broadens the applicability of these molecular tests in various clinical scenarios, thus making them more valuable and attractive. Devices that allow for a variety of applications make for better acquisition decisions since facilities would find the use of such devices more convenient, thereby leading to increased usage. Manufacturers that respond to this growing need produce devices capable of meeting different needs, making them even more appealing on the market.
High Upfront Equipment Costs
The substantial initial cost involved in purchasing the molecular diagnostic tools along with compatible disposables may pose as a hindrance to their implementation by small clinics or laboratories and hinder market penetration. As budget allocations tend to be more conservative, the decision to buy is likely to come only when the return on investment is clearly apparent. This will affect their market penetration in regions where centralized testing continues to dominate.
Regulatory and Reimbursement Challenges
The existence of complex and variable regulations, along with the unpredictability of the reimbursement process for point-of-care molecular tests, presents challenges that can potentially hinder their adoption. The long process of getting approval, as well as having to adjust the evidentiary support depending on the payers' expectations, is another factor that slows down the process and necessitates more effort. If there is no certainty regarding how the tests will be reimbursed, buyers would be less willing to adopt the tests, and this hinders innovation in the field.
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment within the global point-of-care molecular diagnostics industry is influenced by rapid platform development and mergers & acquisitions, whereby the incumbent firms engage in focused acquisitions and partnerships to develop their next-generation molecular chemistries, whereas new entrants bring in disruptive molecular tests into the market. Examples of such M&A and partnering activities include the acquisition of Sherlock by OraSure and the purchase of LEX by QuidelOrtho.
Decentralized Testing Expansion: The demand for molecular tests that are readily available and can be conducted at near-patient locations has led to an increased trend towards decentralizing such test facilities. Decision making and convenience of use become priorities for all parties concerned. Manufacturers are concentrating on developing devices that are portable and ease sample handling by providing training material for non-laboratory personnel. The payer’s interest in deriving value from quicker diagnostics is encouraging the shift to such decentralization in healthcare environments.
Digital Integration and Connectivity: Integration of molecular diagnostics solutions into digital health environments is being driven rapidly through interoperability, which facilitates data exchange and analysis. Interoperability with electronic medical records, telehealth systems, and laboratory information systems helps in generating reports, reducing transcription, and managing patient care. The focus on developing solutions is placed on creating connectivity, user-friendly interfaces, and cloud computing to derive clinical intelligence from assay outputs. Increased digital interoperability will help achieve a larger scale of implementation of point-of-care initiatives, facilitate quality assurance measures, and open novel business opportunities.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means ofPrimary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the major drivers driving the global point-of-care molecular diagnostics market include the urgent need for quick and actionable data, with one of them being the growing use of decentralized diagnostic testing to reduce turnaround time and increase access. Restraints of the market include the significant initial cost of equipment, which may prevent adoption in small clinics. North America is currently the leading geographic region because of its existing presence in the market, favorable regulatory framework, and payment methods, whereas the major leading product segment is PCR-Based Assays due to their reliable performance.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 8.52 Billion |
| Market size value in 2033 | USD 22.85 Billion |
| Growth Rate | 11.52% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Point-of-Care Molecular Diagnostics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Point-of-Care Molecular Diagnostics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Point-of-Care Molecular Diagnostics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Point-of-Care Molecular Diagnostics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Point-Of-Care Molecular Diagnostics Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.5 Billion in 2025 to USD 22.85 Billion by 2033, growing at a CAGR of 11.52% during the forecast period (2026-2033).
Competitive dynamics in the global point-of-care molecular diagnostics market are shaped by rapid platform innovation and consolidation, where incumbents pursue targeted acquisitions and strategic alliances to secure next generation molecular chemistries while startups commercialize disruptive assays. Recent M&A and partnership moves such as OraSure’s acquisition of Sherlock and QuidelOrtho’s purchase of LEX illustrate how CRISPR and ultra-fast PCR technologies are reshaping competitive positioning. 'Roche (cobas Liat)', 'Cepheid (Danaher)', 'Abbott (ID NOW)', 'bioMérieux (BioFire)', 'Hologic (Panther Fusion)', 'Becton Dickinson (BD MAX)', 'GenMark Diagnostics (Roche)', 'Diasorin Molecular', 'Qiagen NV', 'Luminex (DiaSorin)', 'Talis Biomedical', 'Mammoth Biosciences', 'Sherlock Biosciences', 'Lucira Health (Pfizer)', 'LumiraDx', 'BioFire Defense', 'Meso Scale Diagnostics', 'Genetic Signatures', 'Primerdesign (Novacyt)', 'IsoAmp Molecular'
Rapid, accurate diagnosis at or near the patient significantly shortens time to treatment decisions and improves clinical workflows, which in turn encourages adoption of point-of-care molecular diagnostics across care settings. Healthcare providers prioritize technologies that reduce diagnostic uncertainty and enable targeted therapy, driving procurement and integration efforts. The perceived clinical value supports investment by institutions and encourages manufacturers to expand offerings, creating a positive feedback loop that fosters market expansion as stakeholders seek solutions that deliver faster, actionable molecular results outside centralized laboratories.
Decentralized Testing Expansion: Demand for accessible, near patient molecular testing is driving expansion of decentralized testing models in clinics and community sites. Stakeholders prioritize rapid decision making, simplified workflows, and portability to enable testing where patients present. Manufacturers focus on compact platforms, sample handling, training resources to support non laboratory staff. Payer interest in value from faster diagnosis and treatment pathways encourages adoption in care settings. This trend reshapes service delivery, increases testing volumes outside central labs, and fosters partnerships across healthcare providers.
Why does North America Dominate the Global Point-of-Care Molecular Diagnostics Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
